# A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus

> **NCT05411016** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 157 (estimated)

## Conditions studied

- Healthy Volunteers
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus (CLE)

## Interventions

- **DRUG:** Placebo
- **DRUG:** KK4277

## Key facts

- **NCT ID:** NCT05411016
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-03
- **Primary completion:** 2024-12-10
- **Final completion:** 2025-12
- **Target enrollment:** 157 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05411016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05411016, "A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05411016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*